The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

On day 2, tocilizumab was administered ... including intramuscular epinephrine (0.5 mg) and intravenous dopamine (200 mg in 30 mL 0.9% NaCl, administered at 5 mL/h via micropump) to support blood ...

Tocilizumab is a humanized monoclonal antibody targeting the ... The recommended dosage of the subcutaneous injection is 200 mg once every 2 weeks. The dosage may need to be reduced to 150 mg once ...

Prophylactic tocilizumab has the potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies, explained Robert Rifkin, MD, FACP, a medical oncologist and ...

Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

MG University Result 2025: Mahatma Gandhi University (MGU) Nalgonda has recently declared the semester results for various courses like BA, BSc, BCom, LLB, and other exams. Mahatma Gandhi ...

While the 2025 Majestor gets revisions to its exterior and interior design, it still comes with the same powertrain options as its outgoing version Exterior highlights include a huge grille ...

The M9 positions MG in the premium electric MPV segment and will be offered exclusively through the brand's 'Select' dealerships MG to retail the premium M9 MPV via its new ‘Select’ dealerships.

2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled trial (RADIATE) of patients with RA who ...